Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms KODIAC-04
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Oct 2022 Results of pooled analysis from KODIAC 4/5; NCT01309841/NCT01323790 studies, (n=1337) assessing the efficacy of naloxegol in providing clinically meaningful HR-QOL improvement utilizing the patient assessment of constipation quality of life questionnaire (PAC-QOL) in patients with opioid-induced constipation, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.
    • 26 Oct 2022 Results of a pooled analysis assessing symptom improvement utilizing patient assessment of constipation symptoms questionnaire (PAC-SYM) from two randomized, placebo-controlled trials (KODIAC-04 and KODIAC-05) presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 27 Oct 2021 Results from pooled analysis of two trials (KODIAC 4 and 5) assessing initial onset and maintenance of response in subjects with extreme OIC at baseline presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top